FacebookTwitterLinkedInEmail AddressWebsite

Labrix Ledger

Clinical Updates, Research and News

Core Training

Chicago: October 14, 2017

Seats are available for Labrix Core Training in Chicago. Registration is just $150 and includes a free Adrenal Function Panel ($100 value) Register today.

 

Advanced Workshop

Las Vegas, NV: February 9-11, 2018

Early Bird Discount: Save $50

Interested in gaining a deeper understanding of how hormone and neurotransmitter imbalances are affecting your patient’s health? Register today for the Labrix Advanced Workshop to lock in your early bird discount price of $229, a savings of $50! Includes a Free NeuroAdrenal Panel (Value $215).

NAEM

Portland, OR: September 9, 2017

Stop by the Labrix booth at the NAEM conference this Saturday, and learn more about Labrix hormone and neurotransmitter testing.

 

IFM

Dallas, TX: September 11-15, 2017

Labrix will be in Dallas, Texas for the IFM conference next week, where Labrix founders Dr. Jay Mead and Dr. Erin Lommen will be speaking. Stop by the Doctor's Data booth and talk with our National Sales Manager, Heather Cadwallader, and learn more about what's new with Labrix.

 

AARM

Tucson, AZ: October 5-8, 2017

Labrix founder, Dr. Erin Lommen, will be flying to the beautiful city of Tuscon, AZ, to speak at the 15th Annual AARM Conference in mid September. Come take in the sunshine and learn more about adrenal health and minimizing inflammation.

 

Phenibut is an Effective Treatment Tool,

but Must be Used with Caution

 

Published on 9/7/17

Phenibut is an analog of GABA (gamma-aminobutyric acid), the body’s main inhibitory neurotransmitter. GABA’s primary role is that of reducing neuronal excitability throughout the nervous system. Phenibut acts as a GABA receptor agonist, which means that its chemical structure is similar enough to GABA that it acts like GABA at receptor sites, but does not contribute to the secretion or metabolism of GABA. Phenibut has remained a relatively mysterious substance as there is limited information on the prevalence of use, desired effects, toxicity and adverse effects. What limited scientific information does exist is from Russia, where it has been licensed to treat anxiety (especially social anxiety), alcohol withdrawal, stammering and insomnia. Very little of this body of scientific literature has been translated into English.

Phenibut acts primarily on the GABA-B receptor, the same receptor that muscle relaxants like Baclofen act on. However, phenibut has a ten times lower affinity for GABA-B than Baclofen, which means that one has to take higher doses to receive the same benefit. Phenibut also has weak activity at GABA-A receptor sites, which is the receptor responsible for the actions of benzodiazepines, barbiturates and alcohol.

In the US, phenibut is usually available in capsule form, but it is also available online in bulk powder form. Because of the ease of purchasing large quantities over the internet, there have been some reports of toxicity at very high doses. To give an idea of the scale, supplements coming from the US that contain phenibut usually run in the 250 mg per capsule range with the recommendation to use one or two capsules per day. Adverse effects have been reported in the 8g – 40g range. 

The concerns with phenibut seem to lie in the areas of tolerance and dependency when it is used at high doses. However, most adverse reactions have been reported in people who, in addition to using high potencies of phenibut, were also using recreational and prescription drugs that bind to GABA-A receptors, the combination creating an excessively sedating effect.

 Labrix’ Neurobasic panel will identify a patient’s neurotransmitter imbalances, including GABA. Phenibut is known to be an anxiolytic supplement which can assist with sleep and relaxation and can be a welcome addition to a treatment plan for patients with low levels of GABA, or elevations in excitatory neurotransmitters. Before suggesting phenibut to patients, it’s important for providers to be aware of what other medications and supplements their patients are taking to prevent excessive stimulation of GABA receptors.  

 

Resources

1. https://en.wikipedia.org/wiki/Phenibut

2. O'connell CW, Schneir AB, Hwang JQ, Cantrell FL. Phenibut, the appearance of another potentially dangerous product in the United States. Am J Med. 2014;127(8):e3-4.

3. Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2016;35(5):591-6.

4. Samokhvalov AV, Paton-gay CL, Balchand K, Rehm J. Phenibut dependence. BMJ Case Rep. 2013;2013

Disclaimer:

All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.

 

Labrix Core Training

Join the hundreds of practitioners who have attended Labrix live training events and learn more about these exciting opportunities directly from a Labrix attendee and Dr. Jay Mead, Medical Director and co-founder of Labrix.